Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Jun 16

PMID 37323391

Authors

Harshini Kurakula

Swetha Vaishnavi

Mohammed Yaseen Sharif

Satheesh Ellipilli

Affiliations

Soon will be listed here.

Abstract

Small molecule, peptide, and protein-based drugs have been developed over decades to treat various diseases. The importance of gene therapy as an alternative to traditional drugs has increased after the discovery of gene-based drugs such as Gendicine for cancer and Neovasculgen for peripheral artery disease. Since then, the pharma sector is focusing on developing gene-based drugs for various diseases. After the discovery of the RNA interference (RNAi) mechanism, the development of siRNA-based gene therapy has been accelerated immensely. siRNA-based treatment for hereditary transthyretin-mediated amyloidosis (hATTR) using Onpattro and acute hepatic porphyria (AHP) by Givlaari and three more FDA-approved siRNA drugs has set up a milestone and further improved the confidence for the development of gene therapeutics for a spectrum of diseases. siRNA-based gene drugs have more advantages over other gene therapies and are under study to treat different types of diseases such as viral infections, cardiovascular diseases, cancer, and many more. However, there are a few bottlenecks to realizing the full potential of siRNA-based gene therapy. They include chemical instability, nontargeted biodistribution, undesirable innate immune responses, and off-target effects. This review provides a comprehensive view of siRNA-based gene drugs: challenges associated with siRNA delivery, their potential, and future prospects.

Citing Articles

Supramolecular polyrotaxane-based nano-theranostics enable cancer-cell stiffening for enhanced T-cell-mediated anticancer immunotherapy.

Luo H, Lv J, Wen P, Zhang S, Ma W, Yang Z Nat Commun. 2025; 16(1):2331.

PMID: 40057488 PMC: 11890869. DOI: 10.1038/s41467-025-57718-5.

RNA nanotherapeutics for hepatocellular carcinoma treatment.

Yuan Y, Sun W, Xie J, Zhang Z, Luo J, Han X Theranostics. 2025; 15(3):965-992.

PMID: 39776807 PMC: 11700867. DOI: 10.7150/thno.102964.

Integrating Micro- and Nanostructured Platforms and Biological Drugs to Enhance Biomaterial-Based Bone Regeneration Strategies.

Shah S, Sohail M, Nakielski P, Rinoldi C, Zargarian S, Kosik-Koziol A Biomacromolecules. 2024; 26(1):140-162.

PMID: 39621708 PMC: 11733931. DOI: 10.1021/acs.biomac.4c01133.

Nucleic acid drugs: recent progress and future perspectives.

Sun X, Setrerrahmane S, Li C, Hu J, Xu H Signal Transduct Target Ther. 2024; 9(1):316.

PMID: 39609384 PMC: 11604671. DOI: 10.1038/s41392-024-02035-4.

Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management.

Dhingra S, Goyal S, Thirumal D, Sharma P, Kaur G, Mittal N Nanomedicine (Lond). 2024; 19(15):1331-1346.

PMID: 39105754 PMC: 11318747. DOI: 10.1080/17435889.2024.2348438.

References

Belete T . The Current Status of Gene Therapy for the Treatment of Cancer. Biologics. 2021; 15:67-77. PMC: 7987258. DOI: 10.2147/BTT.S302095. View

Liebow A, Li X, Racie T, Hettinger J, Bettencourt B, Najafian N . An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol. 2016; 28(2):494-503. PMC: 5280024. DOI: 10.1681/ASN.2016030338. View

Ding F, Mou Q, Ma Y, Pan G, Guo Y, Tong G . A Crosslinked Nucleic Acid Nanogel for Effective siRNA Delivery and Antitumor Therapy. Angew Chem Int Ed Engl. 2018; 57(12):3064-3068. DOI: 10.1002/anie.201711242. View

Ozpolat B, Sood A, Lopez-Berestein G . Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014; 66:110-6. PMC: 4527165. DOI: 10.1016/j.addr.2013.12.008. View

Fujita Y, Takeshita F, Kuwano K, Ochiya T . RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel). 2013; 6(2):223-50. PMC: 3816685. DOI: 10.3390/ph6020223. View

Syed Y . Givosiran: A Review in Acute Hepatic Porphyria. Drugs. 2021; 81(7):841-848. DOI: 10.1007/s40265-021-01511-3. View

Keam S . Vutrisiran: First Approval. Drugs. 2022; 82(13):1419-1425. DOI: 10.1007/s40265-022-01765-5. View

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

10.

Chen X, Mangala L, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood A . RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2017; 37(1):107-124. PMC: 5898634. DOI: 10.1007/s10555-017-9717-6. View

11.

Samuel M, Chisanga D, Liem M, Keerthikumar S, Anand S, Ang C . Bovine milk-derived exosomes from colostrum are enriched with proteins implicated in immune response and growth. Sci Rep. 2017; 7(1):5933. PMC: 5517456. DOI: 10.1038/s41598-017-06288-8. View

12.

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

13.

Yang K, Zhang C, Wang W, Wang P, Zhou J, Liang X . pH-responsive mesoporous silica nanoparticles employed in controlled drug delivery systems for cancer treatment. Cancer Biol Med. 2014; 11(1):34-43. PMC: 3969802. DOI: 10.7497/j.issn.2095-3941.2014.01.003. View

14.

Apparailly F, Jorgensen C . siRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol. 2012; 9(1):56-62. DOI: 10.1038/nrrheum.2012.176. View

15.

Ziraksaz Z, Nomani A, Soleimani M, Bakhshandeh B, Arefian E, Haririan I . Evaluation of cationic dendrimer and lipid as transfection reagents of short RNAs for stem cell modification. Int J Pharm. 2013; 448(1):231-8. DOI: 10.1016/j.ijpharm.2013.03.035. View

16.

Scott L, Keam S . Lumasiran: First Approval. Drugs. 2021; 81(2):277-282. DOI: 10.1007/s40265-020-01463-0. View

17.

Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y . A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021; 29(7):2219-2226. PMC: 8118699. DOI: 10.1016/j.ymthe.2021.05.004. View

18.

Mittal P, Saharan A, Verma R, Altalbawy F, Alfaidi M, El-Saber Batiha G . Dendrimers: A New Race of Pharmaceutical Nanocarriers. Biomed Res Int. 2021; 2021:8844030. PMC: 7902124. DOI: 10.1155/2021/8844030. View

19.

Liu J, Zhou G, Zhang L, Zhao Q . Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. Front Immunol. 2019; 10:456. PMC: 6433930. DOI: 10.3389/fimmu.2019.00456. View

20.

Bisset D, Stepniak-Konieczna E, Zavaljevski M, Wei J, Carter G, Weiss M . Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet. 2015; 24(17):4971-83. PMC: 4527493. DOI: 10.1093/hmg/ddv219. View